Financial Performance - Total revenue for 2025 reached RMB 16.616 million, a significant increase of 116% compared to RMB 7.681 million in 2024[4] - The company reported a net loss of RMB 131.494 million for 2025, compared to a loss of RMB 116.922 million in 2024, indicating a 12.4% increase in losses[4] - The company's other income and gains increased by 115.6% from approximately RMB 7.7 million in 2024 to about RMB 16.6 million in 2025, primarily due to changes in the fair value of contingent consideration[32] - The annual loss increased from approximately RMB 116.9 million in 2024 to about RMB 131.5 million in 2025[37] - The company reported a pre-tax loss of RMB 145,036,000 for 2025, compared to a loss of RMB 122,820,000 in 2024, indicating a deterioration of 18.1%[40] - The basic and diluted loss per share for the year was RMB 1.11, compared to RMB 0.98 in 2024, indicating a worsening of 13.3%[40] Research and Development - Research and development expenses for 2025 were RMB 89.363 million, up 19.6% from RMB 74.721 million in 2024[4] - The company has established a product pipeline with 3 candidates in clinical stages and 1 in IND approval stage, focusing on oncology and autoimmune diseases[6] - The flagship product HX009 achieved preliminary efficacy data in clinical trials for EBV+ non-Hodgkin lymphoma and melanoma, validating its dual-target mechanism[7] - The first FIC ADC product HX111 received NMPA IND approval, marking a key milestone in the company's ADC strategy[7] - The VersatiBody™ platform successfully advanced two clinical-stage dual-function antibodies, demonstrating high design efficiency and drugability optimization[7] - HX301, a novel oral multi-kinase inhibitor, is in Phase IIa trials targeting four oncogenic pathways, focusing on difficult-to-treat solid tumors like glioblastoma[15] - The autoRx40™ platform is advancing the development of several candidates targeting autoimmune diseases, enhancing the company's capabilities in antibody drug development[23] - The platform strategy allows for efficient iteration and output of candidate drugs, significantly reducing R&D costs and enhancing efficiency, positioning the company for long-term growth[24] Clinical Trials and Product Development - The company initiated a clinical study for HX009 in combination with INX1008 for advanced cholangiocarcinoma, with 9 patients enrolled in 2025[12] - The company aims to prioritize the clinical development of HX009 for EBV+ non-Hodgkin lymphoma, with further evaluation for other indications pending data maturity[10] - The company has expanded its global clinical layout, with simultaneous patient enrollment in China and Australia for HX044[7] - The company is advancing its single-agent treatment with clinical trials in Australia and China, aiming to enroll 8 late-stage solid tumor patients in Australia by 2025 and 18 patients in China by January 2025[13] - HX044 targets ICI-resistant tumors with a dual-target mechanism, establishing a competitive edge in the tumor immunotherapy sector, and will accelerate data collection on safety and efficacy while progressing combination therapy trials[14] - By September 2025, the company plans to initiate clinical studies for HX044 in combination with PD-1 monoclonal antibody, enrolling 2 patients within the year to provide a new treatment option for resistant solid tumors[16] - The Phase I trial for HX301 is expected to demonstrate disease stability in late-stage solid tumor patients at doses of 80mg and above, providing a solid basis for future combination therapies[17] - HX111, the company's first ADC candidate, is set to submit its IND application by the end of 2025, marking a significant milestone in the ADC field, with plans to start Phase I trials in early 2026[19] - The VersatiBody™ platform has successfully produced two FIC clinical-stage dual-function fusion proteins and several ADC candidates, showcasing its efficiency in drug development[22] - The company has established a pipeline consisting of 3 clinical-stage products, 1 IND-approved product, and multiple preclinical candidates, covering tumor immunology, ADC cancer treatment, and autoimmune diseases[25] Financial Position and Cash Flow - As of December 31, 2025, the total cash and cash equivalents amounted to approximately RMB 614.4 million, a 281% increase from about RMB 161.2 million as of December 31, 2024[38] - The current assets were approximately RMB 691.8 million, while current liabilities were about RMB 95.1 million, which included interest-bearing bank loans of approximately RMB 30.0 million[38] - The debt-to-asset ratio decreased from approximately 56.8% as of December 31, 2024, to 20.0% as of December 31, 2025[39] - Total current assets rose to RMB 691,825,000 in 2025, compared to RMB 242,787,000 in 2024, representing an increase of 185.5%[41] - Total liabilities decreased from RMB 197,440,000 in 2024 to RMB 95,114,000 in 2025, a reduction of 51.8%[41] - The company's total assets decreased to RMB 1,034,476,000 in 2025 from RMB 1,001,000,000 in 2024, a decline of 3.2%[41] - The company’s equity increased significantly to RMB 747,619,000 in 2025 from RMB 216,604,000 in 2024, reflecting a growth of 245.5%[42] Administrative and Other Expenses - Administrative expenses increased by 25.2% from approximately RMB 35.5 million in 2024 to about RMB 44.4 million in 2025, mainly due to higher professional service costs and personnel expenses[34] - The company's listing expenses rose by 27.4% from approximately RMB 10.7 million in 2024 to about RMB 13.7 million in 2025, attributed to costs associated with the successful IPO on December 23, 2025[35] - Financial costs increased by 23.4% from approximately RMB 9.4 million in 2024 to about RMB 11.6 million in 2025, mainly due to increased interest on redeemed debt and bank loans[36] Corporate Governance and Shareholder Information - The board of directors does not recommend the payment of a final dividend for the year ending December 31, 2025[79] - The company has adopted corporate governance practices based on the principles and code provisions of the corporate governance code since the listing date[68] - The audit committee, consisting of three independent non-executive directors, has reviewed the consolidated annual results for the year ending December 31, 2025[76] - The company has not engaged in any major litigation or arbitration during the reporting period[72] - The board expresses gratitude to shareholders, customers, and suppliers for their continuous support[83] - The management team and employees are acknowledged for their outstanding achievements and dedication to improving company management[83] - The board includes both executive and non-executive directors, highlighting a diverse leadership structure[85] IPO and Future Plans - The net proceeds from the initial public offering (IPO) on December 23, 2025, amounted to approximately HKD 531.3 million, which remains unutilized[74] - The company plans to allocate 35% of the IPO proceeds (approximately HKD 185.96 million) for the research and development of its core product HX009[74] - 33% of the IPO proceeds (approximately HKD 175.33 million) will be used for the research and development of major products HX301 and HX044[74] - The company has not utilized any of the IPO proceeds since the listing date and plans to use them according to the stated purposes in the prospectus by 2030[75] - There are no significant events following the reporting period up to the date of this announcement[78]
翰思艾泰(03378) - 2025 - 年度业绩